Latest news and press releases about NextCure, Inc. (NXTC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors.
Price
| Price | $6.03 |
| Market Cap | $22M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.38 |
| EV / EBITDA | -0.42 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -175.46% |
| Return on Invested Capital | -259.91% |
| Return on Assets | -188.98% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANTX · BOLD · INTS · ITRM · JSPR · PLUR · PSTV
Explore sector: Healthcare · Biotechnology
More sections of NXTC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks